The Cardiovascular Research Foundation (CRF) announced the 32 late-breaking studies being presented at the Transcatheter Cardiovascular Therapeutics 2022 annual meeting at in Boston, Sept. 16-19.

Progestin-only products may be a "safer alternative" for this patient population, according to a new analysis. 

CBD is generally viewed as a safe, well-tolerated treatment option, but there is still limited research on how it interacts with other medications commonly prescribed by cardiologists. 

The new study, based on data from nearly 3,000 patients, compared DOACs such as rivaroxaban, apixaban and edoxaban with single and dual antiplatelet therapy. 

A two-medication strategy after CABG surgery reduces the risk that grafts will fail, but it also increases the risk of serious bleeding. As one surgeon said, "the benefit comes at a price.”

Elderly patients are often not eligible for oral anticoagulant therapy due to the risk of bleeding events or other adverse outcomes. A very low dose of edoxaban, however, appears to be a safe treatment option, even for especially frail patients.

The new findings, presented during ESC Congress 2022 and published in the New England Journal of Medicine, suggest that prescribing these new-look pills to heart patients could boost outcomes while also improving medication adherence.

The USPSTF recommends statin use for high-risk patients between the ages of 40 to 75 to help prevent a first heart attack or stroke. Other patients in that same age group may also benefit, the group noted, but physician input is needed.